Use of antipsychotic drugs among Dutch youths between 1997 and 2005

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 554-560

  Kalverdijk, Luuk J ^a   Tobi, Hilde ^b   Van Den Berg, Paul B ^c   Buiskool, Janelle ^c   Wagenaar, Leonie ^c   Minderaa, Ruud B ^a   De Jong Van Den Berg, Lolkje T W ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG USE; DRUG UTILIZATION; FEMALE; GROUPS BY AGE; HUMAN; INCIDENCE; INFANT; JUVENILE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRESCRIPTION; PREVALENCE; RISK FACTOR; TREATMENT DURATION;

EID: 50849130261     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2008.59.5.554     Document Type: Article

References (27)

1. Zito JM, Safer DJ, Dosreis S, et al: Psychotropic practice patterns for youth: a 10-year perspective. Archives of Pediatrics and Adolescent Medicine 157:17-25, 2003
2. Patel NC, Crismon ML, Hoagwood K, et al: Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 44:548-556, 2005
3. Cooper WO, Hickson GB, Fuchs C, et al: New users of antipsychotic medications among children enrolled in TennCare. Archives of Pediatrics and Adolescent Medicine 158:753-759, 2004
4. Olfson M, Blanco C, Liu L, et al: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 63:679-685, 2006
5. Curtis LH, Masselink LE, Ostbye T, et al: Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Archives of Pediatrics and Adolescent Medicine 159:362-366, 2005
6. Glazer WM: Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Journal of Clinical Psychiatry 61 (suppl 3):16-21, 2000
7. Malone RP, Sheikh R, Zito JM: Novel antipsychotic medications in the treatment of children and adolescents. Psychiatric Services 50:171-174, 1999
8. Clavenna A, Rossi E, Derosa M, et al: Use of psychotropic medications in Italian children and adolescents. European Journal of Pediatrics 166:339-347, 2007
9. Schirm E, Tobi H, Zito JM, et al: Psychotropic medication in children: a study from the Netherlands. Pediatrics 108:E25, 2001. Available at www.pediatrics.org/cgi/content/full/108/2/e25
10. Hugtenburg JG, Heerdink ER, Egberts AC: Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys. European Journal of Clinical Pharmacology 60:377-379, 2004
11. Bramble D: Annotation: the use of psychotropic medications in children: a British view. Journal of Child Psychology and Psychiatry, and Allied Disciplines 44:169-179, 2003
12. Clark AF: Incidences of new prescribing by British child and adolescent psychiatrists: a prospective study over 12 months. Journal of Psychopharmacology 18:115-120, 2004
13. Haapasalo-Pesu KM, Saarijarvi S, Sorvaniemi M: National prescribing practices of adolescent psychiatrists for psychotropic medications in outpatient care in Finland. Nordic Journal of Psychiatry 57:405-409, 2003
14. Efron D, Hiscock H, Sewell JR, et al: Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 111:372-375, 2003
15. Jensen PS, Buitelaar J, Pandina GJ, et al: Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. European Journal of Child and Adolescent Psychiatry 16:104-120, 2007
16. Tobi H, van den Berg PB, de Jong-van den Berg LTW: The InterAction Database: synergy of science and practice in pharmacy. Lecture Notes in Computer Science 1933:206-211, 2000
17. SPSS, Statistical Package for the Social Sciences (13.0). Chicago, SPSS Inc, 2004
18. Tobi H, van den Berg PB, de Jong-van den Berg LT: Small proportions: what to report for confidence intervals? Pharmacoepidemiology and Drug Safety 14:239-247, 2005
19. Graaf M de, Schouten R, Konijn C: Dutch Social and Mental Health Care for Youth, in Numbers, 1998-2002 [in Dutch]. Amsterdam, Nederlands Instituut voor Zorg en Welzijn, 2005
20. van Daalen E, Buitelaar JK: Prescription of psychopharmacological drugs by child-adolescent psychiatrists in the Netherlands to children and adolescents with psychiatric disorders [in Dutch]. Tijdschrift voor Psychiatrie 41:3-13, 1999
21. Lieberman JA, Tollefson G, Tohen M, et al: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 160:1396-1404, 2003
22. Zito JM, Tobi H, de Jong-van den Berg LT, et al: Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiology and Drug Safety 15:793-798, 2006
23. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 45:771-791, 2006
24. Wudarsky M, Nicolson R, Hamburger SD, et al: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 9:239-245, 1999
25. Troost PW, Lahuis BE, Hermans MH, et al: Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. Journal of Clinical Psychopharmacology 27:52-57, 2007
26. Sikich L, Hamer RM, Bashford RA, et al: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004
27. Tobi H, Scheers T, Netjes KA, et al: Drug utilisation by children and adolescents with mental retardation: a population study. European Journal of Clinical Pharmacology 61:297-302, 2005